Neuropace, Inc. Common Stock earnings per share and revenue
On Jan 13, 2026, NPCE reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -0.15 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 25.46 million, with a --% difference. The market reacted with a +3.84% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 9 analysts forecast an EPS of -0.21 USD, with revenue projected to reach 22.57 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Thermo Fisher Scientific, Inc.
Report Date
Jan 29, 2026 For Q4 25
Estimate
$6.51
Actual
$6.57
Surprise
+0.91%
Intuitive Surgical Inc.
Report Date
Jan 22, 2026 For Q4 25
Estimate
$2.30
Actual
$2.52
Surprise
+9.86%
Hologic Inc
Report Date
Jan 29, 2026 For Q1 26
Estimate
$1.11
Actual
$1.04
Surprise
-6.63%
FAQ
What were Neuropace, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Neuropace, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Neuropace, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 3.84%, changed from $16.13 before the earnings release to $16.75 the day after.
When is Neuropace, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Neuropace, Inc. Common Stock's next earnings report?
Based on 9
analysts, Neuropace, Inc. Common Stock is expected to report EPS of -$0.21 and revenue of $22.57M for Q1 2026.